Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mFolfirinox With or Without Chemoradiotherapy in Borderline Resectable Pancreatic Carcinoma
NCT02676349Phase 2Completed
- Sponsor
- Institut de Cancérologie de Lorraine
- Start
- Oct 2016
- Primary completion
- Apr 2024
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of mFOLFIRINOX, capecitabine in pancreatic carcinoma, sponsored by Institut de Cancérologie de Lorraine. Started Oct 2016; status: completed.
02
Drugs
mFOLFIRINOXcapecitabine
03
Conditions
pancreatic carcinoma
Beyond the preview
Go deeper on NCT02676349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02676349.